Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
SEC Accession No. 0001213900-23-067071
Filing Date
2023-08-14
Accepted
2023-08-14 16:16:55
Documents
12

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ff12023a1_neurosense.htm F-1/A 760726
2 OPINION OF GOLDFARB GROSS SELIGMAN & CO., ISRAELI COUNSEL TO THE REGISTRANT ff12023a1ex5-1_neurosense.htm EX-5.1 11369
3 OPINION OF COVINGTON & BURLING LLP, U.S. COUNSEL TO THE REGISTRANT ff12023a1ex5-2_neurosense.htm EX-5.2 10536
4 CONSENT OF SOMEKH CHAIKIN (MEMBER FIRM OF KPMG INTERNATIONAL), INDEPENDENT REGIS ff12023a1ex23-1_neurosense.htm EX-23.1 2155
5 FILING FEE TABLE ff12023a1ex-fee_neurosense.htm EX-FILING FEES 15457
6 GRAPHIC ex5-1_001.jpg GRAPHIC 14080
7 GRAPHIC ex5-1_002.jpg GRAPHIC 11803
8 GRAPHIC ex5-1_003.jpg GRAPHIC 5044
9 GRAPHIC ex5-2_001.jpg GRAPHIC 9457
10 GRAPHIC ex5-2_002.jpg GRAPHIC 7658
11 GRAPHIC tneuro_logo.jpg GRAPHIC 130396
12 GRAPHIC timage_001.jpg GRAPHIC 265787
  Complete submission text file 0001213900-23-067071.txt   1414053
Mailing Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562
Business Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562 972-9-9531142
NeuroSense Therapeutics Ltd. (Filer) CIK: 0001875091 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: F-1/A | Act: 33 | File No.: 333-273375 | Film No.: 231170470
SIC: 2834 Pharmaceutical Preparations